Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage therapy in the real world: a systematic review and meta-analysis
J Xie, B Xu, L Wei, C Huang, W Liu - Infectious diseases and therapy, 2022 - Springer
Abstract Introduction Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) is the first direct-
acting antiviral (DAA) therapy approved for patients who have previously failed a DAA …
acting antiviral (DAA) therapy approved for patients who have previously failed a DAA …
New direct-acting antivirals for the treatment of patients with hepatitis C virus infection: a systematic review of randomized controlled trials
V Pecoraro, R Banzi, E Cariani, J Chester… - Journal of clinical and …, 2019 - Elsevier
Background New direct-acting antiviral agents (DAAs) approved for the treatment of patients
infected by Hepatitis C virus (HCV) are well tolerated and increase sustained virological …
infected by Hepatitis C virus (HCV) are well tolerated and increase sustained virological …
Machine learning algorithms for predicting direct‐acting antiviral treatment failure in chronic hepatitis C: An HCV‐TARGET analysis
Abstract Background and Aims We aimed to develop and validate machine learning
algorithms to predict direct‐acting antiviral (DAA) treatment failure among patients with HCV …
algorithms to predict direct‐acting antiviral (DAA) treatment failure among patients with HCV …
Self-reported and measured adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs: The HERO …
Background Objective adherence measures, such as electronic blister pack (BP), for direct-
acting antivirals (DAAs) for hepatitis C virus (HCV) treatment have high accuracy, but their …
acting antivirals (DAAs) for hepatitis C virus (HCV) treatment have high accuracy, but their …
Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials
Background Cure rates above 90% have been reported in most Phase III clinical trials using
distinct all-oral direct-acting antivirals (DAAs) in chronic hepatitis C patients. Preliminary …
distinct all-oral direct-acting antivirals (DAAs) in chronic hepatitis C patients. Preliminary …
Efficacy and safety of generic sofosbuvir plus daclatasvir and sofosbuvir/velpatasvir in HCV genotype 3-infected patients: real-world outcomes from Pakistan
Background Direct-acting antivirals (DAAs) therapeutic regimens are highly effective against
chronic hepatitis C virus (HCV) infection. However, HCV patients with genotype 3 (GT3) …
chronic hepatitis C virus (HCV) infection. However, HCV patients with genotype 3 (GT3) …
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter …
CH Liu, CY Peng, CJ Liu, CY Chen, CC Lo… - Hepatology …, 2023 - Springer
Background Real-world data are scarce about the effectiveness and safety of
sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for retreating East Asian patients with …
sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for retreating East Asian patients with …
Hepatitis C virus resistance to the new direct-acting antivirals
I Esposito, J Trinks, V Soriano - Expert opinion on drug metabolism …, 2016 - Taylor & Francis
Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in
recent years with the widespread use of interferon-free combination regimens. Despite the …
recent years with the widespread use of interferon-free combination regimens. Despite the …
Host-targeting therapies for hepatitis C virus infection: current developments and future applications
E Crouchet, F Wrensch, C Schuster… - Therapeutic …, 2018 - journals.sagepub.com
Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases and
hepatocellular carcinoma (HCC) worldwide. In the past few years, anti-HCV therapies have …
hepatocellular carcinoma (HCC) worldwide. In the past few years, anti-HCV therapies have …
Efficacy and safety of alisporivir for the treatment of hepatitis C infection
C Stanciu, A Trifan, C Muzica… - Expert Opinion on …, 2019 - Taylor & Francis
ABSTRACT Introduction: Alisporivir (ALV)(previously known as Debio 025) is a potent,
pangenotypic host-targeting antiviral oral agent acting on cyclophilin A, which is necessary …
pangenotypic host-targeting antiviral oral agent acting on cyclophilin A, which is necessary …